Product news

Share this article:
Novartis and Medicines for Malaria Venture have launched a new pediatric formulation of the malaria treatment Coartem. The product, Coartem Dispersible, is the first artemisinin-based combination therapy (ACT) developed specifically for children, according to a company statement. Novartis will offer the product without profit for public sector use in malaria-endemic regions of Africa.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions